

## **Ulf Tossman joins InnovationsKapital as a new Investment Director in the Healthcare & Life Sciences sector**

Ulf Tossman has joined InnovationsKapital, one of the leading start-up and early stage venture capitalists in the Nordic region, as Investment Director in the Healthcare & Life Sciences team. Ulf Tossman is based at the Stockholm office.

Ulf Tossman has joined InnovationsKapital from Carnegie Asset Management where he held the position of Senior Portfolio Manager, managing a global life science fund. Prior to this he was Executive Vice President, Global R&D at Fresenius Kabi. He also gained extensive experience in drug development and the commercialisation process as Medical Director of Schering Northern Europe and as Project Director of CNS products at Astra Arcus. Ulf Tossman has a PhD in Pharmacology from the Karolinska Institutet.

“Ulf Tossman represents a ‘hard-to-find’ combination of science, business and management experience on an international level and he compliments our team very well”, says Gunnar Fernström, Head of the Life Science team at InnovationsKapital. “His experience is an excellent fit with our strategic direction and focus on Healthcare & Life Science related investments in the Nordic region”.

”I am delighted to join InnovationsKapital”, says Ulf Tossman. “I have great respect for the business approach and competence InnovationsKapital has developed over the years, with a very strong commitment to their portfolio companies and a team-oriented culture. The track record of InnovationsKapital is impressive and I am pleased to be part of the company.”

InnovationsKapital was founded in 1994 and is one of the Nordic regions leading venture capital firms for innovative early stage high growth companies. The business is focused on investments within ICT and HealthCare & Life Sciences, dynamic sectors that are rapidly expanding and where Nordic research plays a leading role. The capital is managed in three funds and is provided by highly reputable Swedish and international institutional investors.

Stockholm September 7, 2005

For further information please contact:

Gunnar Fernström, Investment Director and Head of the Health Care & Life Science team,  
InnovationsKapital (<http://www.innkap.se/>)  
Phone: + 46 31 60 91 90 or + 46 703 12 05 02  
E-mail: [gunnar.fernstrom@innkap.se](mailto:gunnar.fernstrom@innkap.se)

Ulf Tossman, Investment Director, InnovationsKapital (<http://www.innkap.se/>)  
Phone: +46 8 54 50 14 91 or +46 705 63 08 58  
E-mail: [ulf.tossman@innkap.se](mailto:ulf.tossman@innkap.se)